Morphic-Brand-NoTMLogo-RGB-082321-01.png
Morphic Therapeutic to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
05 janv. 2022 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Announces Participation in Upcoming Investor Conferences
03 sept. 2020 16h30 HE | Morphic Therapeutic
WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
25 août 2020 06h30 HE | Morphic Therapeutic
AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development and commercialization WALTHAM, Mass., Aug. 25, 2020 (GLOBE...
MorphicLogo.jpg
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
10 août 2020 07h00 HE | Morphic Therapeutic
Company’s first IND accepted by FDA for MORF-057 in IBDPhase 1 study expected to begin in third-quarter 2020Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM,...
MorphicLogo.jpg
Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
18 juin 2020 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MorphicLogo.jpg
Morphic to Present at the Jefferies Virtual Healthcare Conference
27 mai 2020 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MorphicLogo.jpg
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
06 mai 2020 16h05 HE | Morphic Therapeutic
Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as CFO and COO ...
MorphicLogo.jpg
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
29 avr. 2020 16h15 HE | Morphic Therapeutic
WALTHAM, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MorphicLogo.jpg
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
07 avr. 2020 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer
17 mars 2020 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...